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Abstract. The therapeutic management of recurrent malignant 
gliomas (MGs) is not determined. Therefore, the efficacy of a 
multimodal approach and a combination systemic therapy was 
investigated. A retrospective analysis of 26 MGs patients at 
first relapse treated with multimodal therapy (chemotherapy 
plus surgery and/or reirradiation) or chemotherapy alone 
was performed. Second-line chemotherapy consisted of 
fotemustine (FTM) in combination with bevacizumab (BEV) 
(cFTM/BEV) or followed by third-line BEV (sFTM/BEV). 
Subgroup analyses were performed. Multimodal therapy 
provided a higher overall response rate (ORR) (73 vs. 47%), 
disease control rate (DCR) (82 vs. 67%), median progression-
free survival (mPFS) (11 vs. 7 months; P=0.08) and median 
overall survival (mOS) (13 vs. 8 months; P=0.04) compared 
with chemotherapy. Concomitant FTM/BEV resulted in higher 
ORR (84 vs. 36%), DCR (92 vs. 57%), mPFS (10 vs. 5 months; 
P=0.22) and mOS (11 vs. 5.2 months; P=0.15) compared with 
sFTM/BEV. Methylated patients did not experience additional 
survival benefits with multimodality treatment but had higher 
mPFS (10 vs 7.1 months; P=0.33) and mOS (11 vs. 8 months; 
P=0.33) with cFTM/BEV. Unmethylated patients experienced 
the greatest survival benefit with the multimodal approach 
(mPFS: 10 vs. 5 months; mOS 11 vs 6 months; both P=0.02) 
and cFTM/BEV (mPFS: 5 vs. 2 months; mOS 6 vs. 3.2 months; 
both P=0.01). In conclusion, in recurrent MGs, multimodal 
therapy and cFTM/BEV provide survival and response 
benefits. Methylated patients benefit from a cFTM/BEV but not 
from a multimodal approach. Notably, unmethylated patients 
had the highest survival benefit with the two strategies.
Introduction
Malignant gliomas (MGs) are the most common primary 
malignant brain tumours and include anaplastic gliomas (AG) 
and glioblastoma multiforme (GBM) (1). Maximal safe surgical 
resection followed by radiotherapy with concomitant and adju-
vant temozolomide (TMZ) is the standard first-line treatment 
of GBM (2), leading to a median overall survival (mOS) of 
12-15 months (3). Despite the optimal standard treatment, the 
local infield recurrence rate remains high (~90%), and despite 
the molecular advances, no standard therapies are established 
for recurrent MGs. Different options are under investigation, 
including resurgery, reirradiation and chemotherapy, as well 
as their combinations (3,4).
A recent review of the literature (5) showed a survival benefit 
and an improved functional status after resurgery followed by 
adjuvant treatments, with a higher OS in selected patients with 
favourable clinical and radiological characteristics at the time 
of recurrence. Preoperative Karnofsky Performance Status 
(KPS>70%) and age (<60 years) are important predictors of 
longer survival (5-7). Multiple studies have also demonstrated 
that a greater extent of resection is associated with better 
survival outcomes (8-10). However, prospective data are 
lacking to confirm resurgery as an independent predictor of 
survival (11,12).
Focal radiotherapy is a similarly controversial option due to 
the lack of prospective randomised trials and the risk of toxicity, 
regarding radionecrosis and neurocognitive impairment. Recent 
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advances in radiotherapy techniques, including stereotactic 
and hypofractionated treatments, allow for more precise treat-
ment, sparing healthy surrounding tissue and reducing late 
toxicity (13). Younger age (<70 years) and good performance 
status (PS) (KPS>60%) are the most important predictors of 
longer survival for reirradiation (14). Multiple trials have studied 
the combination of radiotherapy and systemic therapy, such as 
bevacizumab (BEV) and TMZ (13,15,16). Proton-beam therapy 
(PBT), a type of radiation treatment, has the advantage over 
photon-therapy of sparing considerable volumes of previously 
irradiated healthy tissue (13,15). Survival and clinical benefits 
of PBT, alone or in association with chemotherapy, have been 
studied in newly diagnosed and recurrent MGs (17-20).
Many clinical trials on recurrent GBM studied the 
efficacy of single and/or combined chemotherapy agents, 
including nitrosoureas, and of targeted therapies, such as BEV, 
alone or associated with chemotherapy, with encouraging 
results (6,21,22). Nitrosoureas, mainly fotemustine (FTM) (23), 
have been employed either in monotherapy or in combination 
with other agents (21), including BEV, showing potential 
survival benefit (21,24-27).
Improved outcomes with a multimodality management of 
recurrent MGs have been reported in a few trials (28-30), but 
no standard treatment algorithm has been defined.
The aim of this study is to analyse the efficacy of the 
multimodal treatment as a combination of chemotherapy, as 
FTM and BEV in combination or in sequence, and resurgery 
and/or reirradiation, including PBT, in MGs patients at first 
recurrence.
Patients and methods
Study population. This study was conducted at the Department 
of Medical Oncology of Policlinico Umberto I of Rome and 
Latina, both of  Sapienza University of Rome. The study was 
approved by the Institutional Review Board of Latina. 
From August 2011 to August 2017, we retrospectively 
analysed recurrent MGs patients at first relapse treated with 
multimodal therapy as a combination of resurgery and/or 
reirradiation, including PBT, followed by chemotherapy or 
chemotherapy alone. All patients underwent first-line therapy 
with surgery followed by radio-chemotherapy according to 
Stupp protocol (2).
The initial diagnosis was established by magnetic 
resonance imaging (MRI) and histologically using WHO 
criteria (31). Diagnosis of recurrence was assessed by MRI in 
all patients and by histological examination when resurgery 
was performed. Clinical data included patients' characteristics, 
tumour characteristics and treatment information (Table I).
Treatment plan. At first recurrence, patients received either 
a multimodal therapy consisting of chemotherapy preceded 
by resurgery and/or reirradiation or chemotherapy alone. 
Resurgery consisted of maximal safe surgical resection. 
Reirradiation, including radiotherapy or PBT, was given prior 
to chemotherapy and after surgery. Reirradiation consisted of 
fractionated stereotactic radiotherapy (total dose of 60 Gy in 
1.8 to 2.0 Gy fractions). 
Chemotherapy consisted of FTM as second-line therapy in 
combination with BEV (concomitant FTM/BEV; cFTM/BEV) 
or as second-line therapy followed by third-line BEV (sequen-
tial FTM/BEV; sFTM/BEV).
The sequential treatment FTM, according to the Addeo 
schedule (23), consisted of an induction phase dose of 80 mg/mq 
every 2 weeks for 5 consecutive administrations followed by a 
4-week rest period and a maintenance phase dose of 80 mg/mq 
every 4 weeks. BEV was administered at 10 mg/kg every 
2 weeks, in off-label use. In patients who underwent resurgery, 
BEV commenced 4-6 weeks after surgery.
The cFTM/BEV therapy, according to the Soffietti 
schedule (24), consisted of an induction phase with BEV 
at 10 mg/kg on days 1 and 15 and FTM at 75 mg/mq on 
days 1 and 8, followed by a 3-week rest period and a main-
tenance phase with BEV at 10 mg/kg and FTM at 75 mg/mq 
every 3 weeks.
Response evaluation. Radiological evaluations consisted 
of 3-Tesla MRI scans (contrast-enhanced T1-weighted, 
T2/FLAIR-weighted, perfusion-weighted and diffusion-
weighted scans and MR spectroscopy). MRI evaluations were 
made at baseline, between each treatment modality, after the 
first 2 cycles of BEV or after the induction phase of FTM and 
then after every two cycles of BEV or FTM in the maintenance 
phase. Evaluation response was assessed according to RANO 
criteria (32) as complete (CR) and partial (PR) response, 
stable (SD) and progression (PD) disease. Overall response 
rate (ORR) was defined as the sum of CR and PR and disease 
control rate (DCR) was defined as the sum of CR, PR and SD.
Statistical analysis. Survival analysis was conducted on the 
efficacy of multimodal therapy compared to chemotherapy 
alone in terms of median progression-free survival (mPFS) 
and OS (mOS) from diagnosis of recurrence disease and of 
cFTM/BEV versus sFTM/BEV in terms of mPFS and mOS 
from the start of chemotherapy. Median PFS and OS were 
estimated with a 95% confidence interval. Survival curves of 
PFS and OS were generated using the Kaplan-Meier method. 
Differences in PFS and OS were evaluated using the log-rank 
test (Mantel-Cox) for statistical significance, which was 
defined at the P<0.05 level (33).
Subgroup analyses according to t reatment and 
O6-methylguanine-DNA methyltransferase (MGMT) and 
isocitrate dehydrogenase 1 (IDH-1) status were performed. 
Other subgroup analyses according to surgery, radiotherapy 
and other biological markers were not possible to perform due 
to the low number of patients.
Toxicity evaluation. All adverse events were graded according 
to NCI-CTCAE, version 4.03 (34). Toxicity assessment was 
performed at each cycle or, if clinically indicated, at weekly 
intervals. Evaluation of quality of life was not performed due 
to the lack of questionnaires in clinical practice.
Results
Patient characteristics. Twenty-six MGs patients treated 
at first relapse with multimodal therapy or chemotherapy 
were included in the analysis. Patients' characteristics are 
summarised in Table I. The two treatment groups are balanced 
for demographic and clinical characteristics.
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Most patients were male (62%), median age was 50 years 
(range, 26-67 years) and median KPS was 80 (range, 60-100). 
All patients had a histological diagnosis of MGs (77% GBM 
and 23% grade-III gliomas). At first relapse all grade-III 
gliomas evolved into GBM (secondary GBM), a diagnosis that 
was made radiologically in 5 patients and histologically after 
resurgery in 1 patient.
The assessment of MGMT promoter status was conducted 
in all patients and resulted methylated in 16 patients (62%) 
and unmethylated in 10 patients (38%). The assessment of 
IDH status was conducted in 14 patients (54%) and resulted 
mutated in 5 patients (19%) and wild-type in 9 patients (35%).
Fifteen patients (58%) received chemotherapy alone and 
11 patients (42%) received multimodal therapy. Of these, 
2 patients (8%) underwent surgery followed by chemotherapy, 
4 patients (15%) received reirradiation followed by chemo-
therapy and 5 patients (19%) underwent surgery followed by 
reirradiation and then chemotherapy. Twelve patients (46%) 
were treated with cFTM/BEV and 14 patients (54%) with 
sFTM/BEV.
Treatment response evaluation. All patients included in 
the study were assessable for response analysis (Table II). 
Multimodal therapy showed 1 vs. 0 CR (9 vs. 0%), 7 vs. 7 PR 
(64 vs. 47%) and 1 vs. 3 SD (9 vs. 20%) compared to chemo-
therapy alone. ORR and DCR of multimodal therapy were 
73 and 82% compared to 47 and 67% with chemotherapy alone, 
respectively. Concomitant FTM/BEV resulted in 1 vs. 0 CR 
(8 vs. 0%), 9 vs. 5 PR (76 vs. 36%), 1 vs. 3 SD (8 vs. 21%) 
compared to sFTM/BEV. ORR and DCR of cFTM/BEV 
were of 84 and 92% respectively compared to 36 and 57% of 
sFTM/BEV.
General survival outcomes. All patients included in the study 
were assessable for survival analysis (Table II). Median PFS 
and OS from diagnosis of recurrence were 9 months (95% CI 
6.5-11.5) and 11 months (95% CI 9.1-12.9) respectively, 
whereas mPFS and mOS from the start of chemotherapy were 
7.1 months (95% CI 5.6-8.6) and 9.5 months (95% CI 5.1-13.9), 
respectively.
Table I. Continued.
B, Treatment at recurrence
Treatment  n (%)
No. of median cycles
of chemotherapy received (range)
  BEV + FTM  8 (1-24)
  FTM → BEV 5 (1-7)
      FTM
      BEV 8 (2-40)
GBM, Glioblastoma multiforme; MGMT, O6-methylguanine-DNA 
methyltransferase; IDH-1, Isocitrate dehydrogenase 1; RT, Radiotherapy; 
TMZ, Temozolomide; BEV, Bevacizumab; FTM, Fotemustine.
Table I. Patient characteristics and treatment at recurrence (n=26)
A, Patient characteristics at recurrence
Characteristics n (%)
Sex
  Male 16 (62)
  Female 10 (38)
Median age, years (range) 50 (26-67)
Karnofsky performance status
  Median (range) 80 (60-100)
  90-100 9 (35)
  70-80 16 (61)
  60  1 (4)
Laterality
  Right 11 (42)
  Left 15 (58)
Lobe
  Fronto-temporal 7 (27)
  Parieto-temporal 5 (19)
  Monolobar 13 (50)
  Multilobar  1 (4)
Histotype
  Primary GBM 20 (77)
  Secondary GBM 6 (23)
MGMT methylation status at diagnosis
  Methylated 16 (62)
  Unmethylated 10 (38)
IDH-1 status at diagnosis
  Mutated 5 (19)
  Non mutated 9 (36)
  Unknown 12 (46)
First-line therapy
  Stupp protocol (RT/TMZ-TMZ) 26 (100)
B, Treatment at recurrence
Treatment  n (%)
Type of treatment at recurrence
  Multimodal therapy 11 (42)
  Monotherapy   15 (58)
Surgery at recurrence
  Yes 7 (27)
  No 19 (73)
Reirradiation at recurrence
  Yes 9 (35)
  No 17 (65)
Type of reirradiation
  Photon-therapy 4 (15)
  Proton-therapy 5 (19)
Chemotherapy at recurrence
  BEV + FTM 12 (46)
  FTM → BEV 14 (54)
PRELAJ et al:  MULTIMODAL THERAPY IN RECURRENT MALIGNANT GLIOMAS4
Survival outcomes according to treatment. Multimodal therapy 
reported better survival outcomes in terms of mPFS and 
mOS compared to chemotherapy alone. Median PFS was 11 
months (95% CI 8-14) vs. 7 months (95% CI 4.2-9.8) (P=0.08) 
and mOS was 13 months (95% CI 11.2-14.8) vs. 8 months 
(95% CI 5.5-10.5) (P=0.04) (Fig. 1A and B). Concomitant 
FTM/BEV was associated with better survival outcomes 
in terms of mPFS of 10 months (95% CI 8.6-11.4) versus 5 
months (95% CI 1-9) and mOS of 11 (95% CI 10.3-11.7) vs. 
5.2 months (95% CI 1.7-8.7) compared to sFTM/BEV (P=0.22 
and P=0.15, respectively) (Fig.1C and D).
Activity according to MGMT status. Methylated patients 
(n=16) experienced longer survival from the diagnosis of 
recurrence (both mPFS and mOS of 11 vs. 6 months; P=0.03 
and P=0.05, respectively) and from the start of chemotherapy 
(mPFS: 8.2 vs. 3.8 months, P=0.11; mOS: 10.6 vs. 5 months, 
P=0.08), independently of the type of treatment. In methyl-
ated patients, multimodal treatment (n=8) was associated with 
similar mPFS (both 11 months) and mOS (12 vs. 11 months) 
compared to chemotherapy alone (n=8). Methylated patients 
experienced greater mPFS (10 vs. 7.1 months; P=0.33) and 
mOS (11 vs. 8 months; P=0.33) with cFTM/BEV (n=6) 
compared to sFTM/BEV (n=10) (Fig. 2A and B).
The greatest benefit was observed in unmethylated patients 
who experienced statistically significant longer survival with 
multimodal therapy and cFTM/BEV. Unmethylated patients 
experienced higher mPFS (10 vs. 5 months; P=0.02) and mOS 
(11 vs. 6 months; P=0.02) with multimodal therapy (n=3) 
compared to chemotherapy alone (n=7) and greater mPFS 
(5 vs. 2 months; P=0.01) and mOS (6 vs. 3.2 months; P=0.01) 
with cFTM/BEV (n=6) compared to sFTM/BEV (n=4) 
(Fig. 2C and D).
Toxicity evaluation. All patients were evaluated for safety. 
Concomitant FTM/BEV was well-tolerated with grade 1-2 
myelotoxicities in 62 vs. 70% of patients, grade 3 myelotoxicity 
in 8 vs. 15% of patients and grade 1-2 hypertransaminasemia 
in 23 vs. 38% of patients compared to sFTM/BEV. Grade 1-2 
fatigue was present in 30% of patients in both treatments. 
Grade 1-2 hypertension and proteinuria developed in 10 and 
15% of patients in cFTM/BEV vs. 20% and 40% of patients in 
sFTM/BEV. No grade 4 adverse events were observed. None 
of the patients discontinued for toxicity.
Discussion
For recurrent MGs, different treatment strategies are available, 
such as resurgery, reirradiation and systemic chemotherapy, 
as well as their combinations, depending on clinical status, 
tumour location and extension and time interval since last 
treatment. Nonetheless, the optimal management of recurrent 
MGs has not yet been established, which represents a marked 
clinical challenge.
Local recurrence within 2 cm of the resection bed of 
the primary tumour is the most common pattern of failure. 
Therefore, local strategies such as surgical resection and/or 
radiotherapy in combination with systemic chemotherapy, in 
a multidisciplinary approach, may offer an advantage in local 
control and may improve survival outcomes.
Recent literature reviews and several retrospective 
studies suggest a survival benefit with reoperation at the 
time of recurrence. Favourable PS and extent of resection 
(gross total resection vs. partial surgery) are the main 
predictors of survival (5-10) and the addition of adjuvant 
treatments (chemotherapy and radiosurgery) prolongs 
survival (5,35,36).
Table II. Results for objective response and survival outcomes according to type of approach and treatment.
 Multimodal Monotherapy Concomitant Sequential
Variables therapy (n=11) (n=15) FTM/BEV (n=12) FTM/BEV (n=14)
Objective response, n (%)
  CR 1 (9%) 0 (0%) 1 (8%) 0 (0%)
  PR 7 (64%) 7 (47%) 9 (76%) 5 (36%)
  SD 1 (9%) 3 (20%) 1 (8%) 3 (21%)
  PD 2 (18%) 5 (33%) 1 (8%) 6 (43%)
  ORR 73 47 84 36
  DC 82 67 92 57
Survival data 
  6 months-PFS, %  82 67 92 71
  12 months-PFS, %  27 20 25 21
Median PFS, months 11 7 10 5
  6 months-OS, %   91 73 83 50
  12 months-OS, % 55 20 25 21
Median OS, months 13 8 11 5.2
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DC, disease control; 
FTM, fotemustine; BEV, bevacizumab; PFS, progression-free survival; OS, overall survival.
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Figure 1. Survival outcomes according to treatment. Kaplan-Meier curves for (A) PFS and (B) OS in MGs patients treated with multimodal therapy com-
pared to chemotherapy alone and for (C) PFS and (D) OS in MGs patients treated with concomitant FTM/BEV compared to sequential FTM/BEV. PFS, 
progression-free survival; OS, overall survival; MGs, malignant gliomas; FTM, fotemustine; BEV, bevacizumab.
Figure 2. Survival outcomes according to MGMT-methylation. Kaplan-Meier curves for (A) PFS and (B) OS in methylated patients and for (C) PFS and (D) OS 
in non-methylated patients treated with concomitant FTM/BEV compared to sequential FTM/BEV. MGMT, O6-methylguanine-DNA methyltransferase; PFS, 
progression-free survival; OS, overall survival; MGs, malignant gliomas; FTM, fotemustine; BEV, bevacizumab.
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Several trials suggest an improvement in survival and 
functional status with local reirradiation in younger patients 
with good PS, tumour size <4 cm and progression more than 
6 months from first irradiation (14,37,38). Retrospective and 
prospective trials have investigated the benefits of reirradiation 
as adjuvant therapy after resurgery (36) or as part of a combined 
approach with chemotherapy (39). There is no consensus on 
one particular radiation regimen, but higher doses per fraction 
with modern precision radiotherapy (PBT, fractionated 
stereotactic radiotherapy or stereotactic radiosurgery), are 
associated with smaller recurrences and clinical efficacy with 
low toxicity rates. Systemic agents used as radiosensitizers 
in combination with radiotherapy are cytotoxic and targeted 
systemic agents, such as TMZ and BEV (38).
Systemic therapy, consisting of chemotherapeutic and 
anti-angiogenetic drugs, is the main treatment employed 
and investigated for recurrent gliomas as single agents or as 
combination regimens (21,30), but the optimal combination 
and sequencing have not yet been established. The most used 
drugs are rechallenge TMZ, nitrosoureas and BEV (40).
According to several systematic reviews and meta-
analyses, BEV as a single agent and in combination with 
chemotherapy, both as first or second-line treatments, has 
been shown to be effective in terms of ORR, PFS and reducing 
symptoms, but not in terms of OS (5,41).
Interesting results were shown with the combination of 
BEV and nitrosoureas (41,42), such as lomustine and FTM. 
The BELOB phase II trial (42), the subsequent phase III trial 
EORTC-26101 (43) and two recent trials (44,45) showed that 
the combination BEV/lomustine at first recurrence was supe-
rior to BEV or lomustine monotherapy (41). Other interesting 
results were obtained by retrospective and prospective trials on 
the combination of BEV and FTM (24-27) (Table III). Soffietti 
et al. showed the efficacy of the association of BEV/FTM at 
first recurrence in recurrent grade-III gliomas (24) and GBM 
patients, in terms of survival outcome and response rate (26). 
Similar results were reported by a retrospective analysis 
conducted by Liu et al (27) and an observational prospective 
study by Vaccaro et al (25).
Several studies showed that the efficacy of systemic chemo-
therapy in terms of disease control and survival is improved by 
the combination with local treatments such as surgery and/or 
irradiation (28-30,39,46) (Table IV). In 2015 Scorsetti et al (30) 
evaluated 43 GBM patients treated by chemotherapy plus local 
treatment or chemotherapy alone, showing that the combined 
treatment achieved better survival results in terms of PFS (15 
vs. 5 months) and OS (17 vs. 6 months).
Azoulay et al (39) conducted a retrospective study to assess 
the benefits of resurgery followed by chemotherapy and/or reir-
radiation compared to resurgery alone and chemotherapy and/
or reirradiation. Median survival was superior in the multi-
modal treatment compared to the other treatment approaches 
(10 vs. 6.8 vs. 6.6 months).
Archavlis et al. showed in three clinical studies (28,29,46) 
that a combined therapy of resurgery, brachytherapy and 
chemotherapy achieved better survival outcomes compared to 
a historical control group of patients treated with TMZ.
We report our experience with the multimodal manage-
ment of recurrent MGs, as the combination of resurgery and/or 
radiotherapy and chemotherapy, compared to chemotherapy 
alone. In regards to chemotherapy, we studied the efficacy of 
cFTM/BEV compared to sFTM/BEV, an idea born from the 
study of Piccioni et al (47), which demonstrated equal efficacy 
of BEV monotherapy on first, second or third recurrence in 
recurrent GBM.
We observed that multimodal therapy was associated 
with 25% higher response rates, 15% higher DCR and a 
survival improvement of 4 months in PFS and 5 months in OS 
compared to chemotherapy alone. Our results are in line with 
those reported by other retrospective and prospective trials 
on multimodal treatment (Table IV), showing the possibility 
of combining systemic chemotherapy with local treatment to 
improve local control of the disease and survival outcomes.
According to the type of chemotherapy, we observed ~50% 
higher response rates, 35% higher DCR and better survival 
outcomes with cFTM/BEV compared to sFTM/BEV. Our 
results seem to be stronger than those reported by other trials 
regarding cFTM/BEV (Table III), which was probably due to 
the addition of reirradiation, alone or after surgery.
Only recently, the DIRECTOR and the BELOB trials 
demonstrated the prognostic value of the MGMT methylation 
also in recurrent GBM (42,48,49). The AVAREG trial (50) 
demonstrated also that MGMT methylation status was predic-
tive of efficacy of FTM in the recurrence setting. We observed 
an association between MGMT methylation and longer 
survival independent of the type of treatment. Methylated 
patients appear not to benefit from a multimodal approach, 
but a survival benefit was observed with the combination 
therapy compared to FTM alone, whereas unmethylated 
patients appear to benefit from both multimodal therapy and 
concomitant systemic therapy better than methylated patients. 
Subgroup analyses on MGMT methylation in this setting were 
not reported in other similar clinical trials (Table III-IV). 
Similar to the other trials on cFTM/BEV, the combination 
therapy was well-tolerated, with most frequent grade 3-4 
toxicities related to chemotherapy.
The main limitations of this study are the low number of 
patients with small subgroups resulting in a lack of statistically 
significant results, the heterogeneity and non-standardisation 
in the therapeutic approach used, and the retrospective and 
non-randomised nature, resulting in possible selection biases 
for each treatment modality.
Despite these limitations our encouraging survival and 
local control results underlined that the management of recur-
rent MGs patients, especially those with a poorer survival such 
as unmethylated patients, should involve a multidisciplinary 
approach, associating local treatments (surgery and/or radio-
therapy) to chemotherapy, or a combination of chemotherapies, 
whenever possible. Moreover, in this multimodal view of the 
treatment of MGs patients, molecular characteristics play 
a relevant role in the decision making to determine the best 
choice of treatment and the highest survival benefit possible.
Considering that no optimal treatment combinations and 
sequencing have been established, our results could be a 
starting point for further larger prospective studies.
In conclusion, our experience showed that in MG patients 
at first recurrence, multimodal treatment (chemotherapy plus 
surgery and/or radiotherapy) achieves better survival and 
response results compared to chemotherapy alone. Moreover, 
concomitant BEV/FTM provides higher survival benefit and 
PRELAJ et al:  MULTIMODAL THERAPY IN RECURRENT MALIGNANT GLIOMAS8
response rates, without adding higher toxicity, compared to the 
sequential approach. Better survival outcomes were observed 
in MGMT methylated patients but MGMT unmethylated 
patients have shown a greater survival benefit with both multi-
modal therapy and cFTM/BEV.
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